# OnCo record nct02972840 (trial). Data CC BY-NC 4.0, attribute "Data from OnCo (onco.cc)". Whole corpus: https://onco.cc/api/v1/onco.nt
@prefix schema: <https://schema.org/> .
@prefix onco: <https://onco.cc/ns#> .
@prefix xsd: <http://www.w3.org/2001/XMLSchema#> .

<https://onco.cc/trials/nct02972840/>
  a schema:MedicalTrial ;
  onco:kind "trial" ;
  schema:identifier "nct02972840", "NCT02972840" ;
  schema:name "A Study of BR Alone Versus in Combination With Acalabrutinib in Subjects With Previously Untreated MCL"@en ;
  schema:alternateName "ECHO"@en, "Acalabrutinib with bendamustine and rituximab in untreated mantle cell lymphoma"@en ;
  schema:description "A phase 3 trial of Acalabrutinib, Bendamustine and Rituximab in mantle cell lymphoma, run by Acerta Pharma BV, active and no longer recruiting."@en ;
  schema:url <https://onco.cc/trials/nct02972840/> ;
  schema:dateModified "2026-09-16"^^xsd:date ;
  schema:citation <https://clinicaltrials.gov/study/NCT02972840> ;
  onco:status "active" ;
  onco:tag "pipeline", "ctgov-ingest" ;
  onco:phase "3" ;
  schema:startDate "2017-04-05" ;
  onco:related <https://onco.cc/roadmaps/lymphoma-roadmap/>, <https://onco.cc/key-papers/paper-echo-acalabrutinib-bendamustine-rituximab-mantle-cell-jco-2025/>, <https://onco.cc/trials/shine/>, <https://onco.cc/trials/enrich/> ;
  onco:cancers <https://onco.cc/cancers/mantle-cell-lymphoma/> ;
  onco:technologies <https://onco.cc/technologies/cytotoxic-chemotherapy/>, <https://onco.cc/technologies/kinase-inhibitors/>, <https://onco.cc/technologies/monoclonal-antibody/> ;
  onco:targets <https://onco.cc/targets/btk/>, <https://onco.cc/targets/cd20/>, <https://onco.cc/targets/ccnd1/> ;
  onco:drugs <https://onco.cc/drugs/acalabrutinib/>, <https://onco.cc/drugs/bendamustine/>, <https://onco.cc/drugs/rituximab/> ;
  onco:companies <https://onco.cc/companies/astrazeneca/> ;
  onco:pathways <https://onco.cc/pathways/bcr-signalling/> ;
  onco:keyPapers <https://onco.cc/key-papers/paper-echo-acalabrutinib-bendamustine-rituximab-mantle-cell-jco-2025/> .